LONDON (Alliance News) - E-Therapeutics PLC on Monday said the top-line results from its phase 2b trials for its ETS6103 anti-depressant failed to meet the primary endpoint.
The company said ETS6103 did not meet the primary endpoint from an efficacy standpoint, which had been to establish non-inferiority of the drug against amitriptyline, a currently-used tricyclic treatment.
Further analysis will be undertaken but the company said its conclusion was ETS6103 was not non-inferior to amitriptyline from an efficacy view, though the overall results were similar to what it had hoped.
Shares in the company plunged on the news, however, down 38% to 16.00 pence to sit among the worst performers in the AIM All-Share early Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
